Jan. 15 at 1:06 PM
Cantor yesterday⬆️
$EPRX's PT to
$19 and reit'd at Overweight while adding to its 2026 Top Pick after🗣️w/ EPRX mgmt., around the recent data/progress/next steps around EP-104GI in eosinophilic esophagitis.
$SNY
Here's what Cantor had to say:
Recall the Diffusphere technology is meant to potentially allow for once a year administration, which could be added on top of patients undergoing annual endoscopies.
We are also newly announcing EPRX as a top pick, more on this below.
We would own the name ahead of the Phase 2b data expected in 3Q26.
We updated our prevalence estimates by using a recent claims database study focusing on the U.S. EoE population. This led to an increase in our peak sales estimates and an increase in our 12-month PT to
$19 (from
$11). Our prevalence numbers are still conservative in our view.
